-
ISSCR Supports Amendment in U.S. Congress to Prevent Fetal Tissue Research Funding Restrictions
The ISSCR and other medical, scientific, educational, and healthcare groups sent a letter to members of the U.S. Congress supporting an amendment that would prevent the implementation of a new policy to restrict and delay federal funding for fetal tissue research.Full story -
ISSCR Applauds Landmark Court Ruling in Favor of FDA Regulating Stem Cell Therapies Offered by Florida Clinic
The ISSCR commends the U.S. District Court ruling that confirms the FDA’s authority to regulate clinics marketing and selling unproven therapies as stem cell products. The clinic, U.S. Stem Cell, has injected cells derived from fat into the eyes of several patients, resulting in at least three being blinded.Full story -
ISSCR Opposes Health and Human Services Policy Restricting Fetal Tissue Research
The International Society for Stem Cell Research (ISSCR), the largest professional organization of stem cell researchers from around the world, opposes the new U.S. Health and Human Services policy to eliminate federal funding for fetal tissue research in the National Institutes of Health (NIH) intramural research program. This research has long been viewed as good public policy to improve human health and has proceeded with public support.Full story -
ISSCR Applauds Health Canada’s New Policy Statement re Autologous Cell Therapy Products
The ISSCR welcomes the new policy guidance from Health Canada that clarifies the regulation of autologous cell products in Canada. The new policy guidance aligns Canada’s regulations with the U.S. Food and Drug Administration’s 2017 Regenerative Medicine Framework and the Australian Therapeutic Goods Administration’s 2018 Autologous human cell and tissue product regulations.Full story -
ISSCR Commends U.S. House of Representatives Committee for Approval of NIH Funding Bill
The Appropriations Committee of the U.S. House of Representatives has approved a $2 billion increase for the National Institutes of Health (NIH) and defeated an amendment that would have prohibited federal funding for fetal tissue research.Full story -
Stem Cell Therapies and Regenerative Medicine Moving Toward the Clinic
Stem cell research is leading to potential new therapies to treat disease, with several applications in clinical trials or expected to enter trials in the coming months. These new discoveries are transforming how we think of medicine and will be key to discussions at the International Society for Stem Cell Research annual meeting, 26-29 June at the Los Angeles Convention Center.Full story -
ISSCR Applauds New Japanese Rules Allowing Human-to-Animal Chimeric Embryo Research
The ISSCR supports research using human-animal chimeras conducted under appropriate review and oversight (ISSCR Guidelines Recommendation 2.1.5) and applauds the new Japanese rules enabling research on chimeric embryos.Full story -
ISSCR 2019 Election Results
ISSCR has elected its next leadership slate, with leaders beginning their terms after the 2019 annual meeting. On behalf of all members, we extend congratulations to newly-elected officers Melissa Little, vice president; and Kenneth Zaret, treasurer, and re-appointed board members Marianne Bronner, Valentina Greco, and Arnold Kriegstein.Full story -
Progress in Stem Cell Science & Regenerative Medicine On Tap in Los Angeles, 26-29 June
Top scientists and researchers from academia, medicine, and industry will gather to share groundbreaking stem cell science and its translation to clinical application at the annual meeting of the International Society for Stem Cell Research (ISSCR), 26-29 June in Los Angeles, Calif.Full story -
ISSCR Announces 2019 Award Recipients
The ISSCR announces the recipients of its 2019 Award for Innovation, Dr. Susan Lim Award for Outstanding Young Investigator, Tobias Award Lecture, and Public Service Award. Awardees will be recognized at the ISSCR annual meeting, 26-29 June, in Los Angeles, Calif., U.S.Full story -
ISSCR Introduces Chief Operating Officer Keith Alm
Keith Alm joined the ISSCR as chief operating officer in January 2019, after serving as a brand strategist and consultant for the society for nearly a decade. He’s worked with many of the organization's leaders on strategic positioning, communications, and partnerships.Full story -
ISSCR Testimony in U.S. Congress Regarding Need for Fetal Tissue Research
In written and oral testimony before the U.S. House of Representatives Oversight and Government Reform Committee today, former ISSCR president Sally Temple describes fetal tissue research as essential in studying and developing therapies for cancer, HIV, Zika, tuberculous, and other devastating diseases.Full story -
ISSCR Comments on Reports of Chinese Scientists Performing Genome-Editing During Fertility Treatment
Reports indicate that scientists in China have used CRISPR-mediated genome editing during in vitro fertilization to modify the genetic material of two embryos that were subsequently implanted into a patient, leading to the birth of two babies. As ISSCR and a number of other organizations have previously stated, the use of nuclear genome editing technologies, such as CRISPR, during fertility treatment is premature and should not be attempted at this time.Full story -
ISSCR Applauds FDA, FTC for Holding Deceptive Stem Cell Clinics Accountable
The U.S. Food and Drug Administration has issued a warning letter to StemGenex of San Diego after an investigation found its cellular therapy does not conform with good manufacturing practice requirements, is being illegally marketed to treat conditions for which it has not been proven safe or effective, and is putting patients at risk.Full story -
ISSCR Comments on Horizon Europe
The ISSCR has responded to the European Commission proposal and the European Parliament's amendments for Horizon Europe, the seven-year research and innovation funding program to follow Horizon 2020.Full story